Alnylam Expands Senior Leadership Team with Two Key Appointments
− Company Appoints Senior Vice President, Head of
"We are pleased to have Masako and Jing join us at an exciting crossroads in Alnylam’s journey from an R&D to a commercial organization. We look forward to their insights on expanding our global footprint and ensuring patients worldwide have access to the innovative medicines we are developing," said John Maraganore, Ph.D. Chief Executive Officer of Alnylam.
"Extending Alnylam's operations into the Asian region, particularly Japan, is a critical step in preparing to launch RNAi therapeutics globally," commented Ms. Nakamura. "Leveraging my expertise in introducing and commercializing orphan drugs in Asian and global markets, I look forward to charting the Company's course from a research and development organization to a multi-product commercial organization and improving the lives of patients with rare diseases one patient at a time."
In this role, Ms. Nakamura will be responsible for the strategic
direction and execution of Alnylam’s operations in the Asian region with
an initial focus on
Ms. Nakamura comes with over 25 years of rare disease/orphan drug
biotech industry experience. Most recently, she served as Head of
“It’s a pleasure to join Alnylam, a company with a patient-focused mindset and a robust patient access philosophy,” said Dr. Marantz. “Integration of clinical and commercial strategy is critical to seamless entry of novel medicines into the rare disease marketplace, while keeping patient needs top of mind. I hope to offer many learnings to help facilitate this integration.”
In her role, Dr. Marantz will be responsible for the strategic direction and oversight of Alnylam’s Medical Affairs expertise area. She and her team will serve as a key interface between clinical and commercial activities, responsible for building and executing scalable global medical affairs strategies across product life cycles. Under her leadership, the Medical Affairs organization will continue to be highly patient focused and responsible for providing scientific and medical expertise and support for Alnylam’s products and pipeline to all external stakeholders. It will also help establish Alnylam as a trusted scientific partner with medical and patient communities.
Dr. Marantz brings over 18 years of pharmaceutical experience with an
extensive background in medical affairs. Most recently, she was Vice
President, Global Medical Affairs, Complement Franchise at Alexion after
serving as Head of U.S. Medical Affairs, responsible for three marketed
rare disease products across hematology, nephrology, metabolic, and
neurology indications. Previously, she was the Global Medical Lead for
TECFIDERA®, Biogen’s flagship product in neurology. Prior to
her role at Biogen, Dr. Marantz held senior leadership positions at
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development. Looking forward, Alnylam will continue to execute on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam employs over 800 people in the U.S. and
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam's views with respect to global commercialization of investigational RNAi therapeutics, including the potential timing for the launch of patisiran and other investigational medicines in Asian territories, and expectations regarding "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, Alnylam's ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its product candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all, actions or advice of regulatory agencies, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing, delays, interruptions or failures in the manufacture and supply of its product candidates, obtaining, maintaining and protecting intellectual property, Alnylam's ability to enforce its intellectual property rights against third parties and defend its patent portfolio against challenges from third parties, obtaining and maintaining regulatory approval, pricing and reimbursement for products, progress in establishing a commercial and ex-United States infrastructure, competition from others using technology similar to Alnylam's and others developing products for similar uses, Alnylam's ability to manage its growth and operating expenses, obtain additional funding to support its business activities, and establish and maintain strategic business alliances and new business initiatives, Alnylam's dependence on third parties for development, manufacture and distribution of products, the outcome of litigation, the risk of government investigations, and unexpected expenditures, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (
Patisiran, givosiran, and lumasiran have not been approved by the
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom, 617-682-4340
(Investors and Media)
Josh Brodsky, 617-551-8276